Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
55
PODD Quote, Financials, Valuation and Earnings
Last price:
$288.31
Seasonality move
:
-0.29%
Day range:
$285.08 - $289.91
52-week range:
$230.05 - $354.88
Dividend yield:
0%
P/E ratio:
83.80x
P/S ratio:
8.29x
P/B ratio:
14.68x
Volume:
294.3K
Avg. volume:
771K
1-year change:
9.72%
Market cap:
$20.3B
Revenue:
$2.1B
EPS (TTM):
$3.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$679M | $1.15 | 28.59% | 5.4% | $377.72 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.51% | -71.7% | $144.43 |
|
BSX
Boston Scientific Corp.
|
$5B | $0.71 | 15.97% | 105.65% | $125.86 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.4B | $1.99 | 12.86% | 19.35% | $599.60 |
|
RMD
ResMed, Inc.
|
$1.3B | $2.50 | 8.96% | 16.17% | $291.80 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$235.8M | -$0.34 | -2.02% | -4.07% | $24.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$288.82 | $377.72 | $20.3B | 83.80x | $0.00 | 0% | 8.29x |
|
ABT
Abbott Laboratories
|
$124.81 | $144.43 | $217B | 15.66x | $0.59 | 1.89% | 4.98x |
|
BSX
Boston Scientific Corp.
|
$96.13 | $125.86 | $142.5B | 51.42x | $0.00 | 0% | 7.42x |
|
ISRG
Intuitive Surgical, Inc.
|
$577.15 | $599.60 | $204.6B | 76.39x | $0.00 | 0% | 21.83x |
|
RMD
ResMed, Inc.
|
$244.44 | $291.80 | $35.7B | 25.02x | $0.60 | 0.93% | 6.84x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$22.48 | $24.81 | $1.5B | -- | $0.00 | 0% | 1.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PODD
Insulet Corp.
|
42.7% | 1.380 | 4.75% | 1.89x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.345 | 8.31% | 0.81x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.065 | -- | 3.42x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.243 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$513.5M | $117.7M | 9.14% | 18.92% | 16.66% | $94.6M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Insulet Corp. vs. Competitors
-
Which has Higher Returns PODD or ABT?
Abbott Laboratories has a net margin of 12.4% compared to Insulet Corp.'s net margin of 14.07%. Insulet Corp.'s return on equity of 18.92% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About PODD or ABT?
Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 30.78%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.72%. Given that Insulet Corp. has higher upside potential than Abbott Laboratories, analysts believe Insulet Corp. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.19 2 0 ABTAbbott Laboratories15 7 0 -
Is PODD or ABT More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock PODD or ABT?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. Insulet Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PODD or ABT?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Insulet Corp.'s net income of $87.6M is lower than Abbott Laboratories's net income of $1.6B. Notably, Insulet Corp.'s price-to-earnings ratio is 83.80x while Abbott Laboratories's PE ratio is 15.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.29x versus 4.98x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.8.29x 83.80x $706.3M $87.6M ABTAbbott Laboratories4.98x 15.66x $11.4B $1.6B
-
Which has Higher Returns PODD or BSX?
Boston Scientific Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 14.91%. Insulet Corp.'s return on equity of 18.92% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About PODD or BSX?
Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 30.78%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 30.93%. Given that Boston Scientific Corp. has higher upside potential than Insulet Corp., analysts believe Boston Scientific Corp. is more attractive than Insulet Corp..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.19 2 0 BSXBoston Scientific Corp.25 2 0 -
Is PODD or BSX More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.
-
Which is a Better Dividend Stock PODD or BSX?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or BSX?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Insulet Corp.'s net income of $87.6M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Insulet Corp.'s price-to-earnings ratio is 83.80x while Boston Scientific Corp.'s PE ratio is 51.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.29x versus 7.42x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.8.29x 83.80x $706.3M $87.6M BSXBoston Scientific Corp.7.42x 51.42x $5.1B $755M
-
Which has Higher Returns PODD or ISRG?
Intuitive Surgical, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 28.31%. Insulet Corp.'s return on equity of 18.92% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About PODD or ISRG?
Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 30.78%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.89%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.19 2 0 ISRGIntuitive Surgical, Inc.14 11 1 -
Is PODD or ISRG More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock PODD or ISRG?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or ISRG?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Insulet Corp.'s net income of $87.6M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Insulet Corp.'s price-to-earnings ratio is 83.80x while Intuitive Surgical, Inc.'s PE ratio is 76.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.29x versus 21.83x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.8.29x 83.80x $706.3M $87.6M ISRGIntuitive Surgical, Inc.21.83x 76.39x $2.5B $709.2M
-
Which has Higher Returns PODD or RMD?
ResMed, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 26.1%. Insulet Corp.'s return on equity of 18.92% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About PODD or RMD?
Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 30.78%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.38%. Given that Insulet Corp. has higher upside potential than ResMed, Inc., analysts believe Insulet Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.19 2 0 RMDResMed, Inc.8 7 1 -
Is PODD or RMD More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock PODD or RMD?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.60 per share. Insulet Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PODD or RMD?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Insulet Corp.'s net income of $87.6M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Insulet Corp.'s price-to-earnings ratio is 83.80x while ResMed, Inc.'s PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.29x versus 6.84x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.8.29x 83.80x $706.3M $87.6M RMDResMed, Inc.6.84x 25.02x $1.3B $348.5M
-
Which has Higher Returns PODD or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of -8.49%. Insulet Corp.'s return on equity of 18.92% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About PODD or TNDM?
Insulet Corp. has a consensus price target of $377.72, signalling upside risk potential of 30.78%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 10.36%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.19 2 0 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is PODD or TNDM More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.
-
Which is a Better Dividend Stock PODD or TNDM?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or TNDM?
Insulet Corp. quarterly revenues are $706.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Insulet Corp.'s net income of $87.6M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Insulet Corp.'s price-to-earnings ratio is 83.80x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 8.29x versus 1.49x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.8.29x 83.80x $706.3M $87.6M TNDMTandem Diabetes Care, Inc.1.49x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
